ID   2fTGH-U1A
AC   CVCL_A3FC
SY   U1A; 11,1
DR   cancercelllines; CVCL_A3FC
DR   Wikidata; Q105505902
RX   PubMed=2513475;
CC   Population: Caucasian.
CC   Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080. Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P0A9M5; Escherichia coli gpt.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Transformant: ChEBI; CHEBI:132982; Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride; Acridine mutagen ICR 191).
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0115 ! 2fTGH
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 10-09-24; Version: 9
//
RX   PubMed=2513475; DOI=10.1128/mcb.9.11.4605-4612.1989; PMCID=PMC363606;
RA   Pellegrini S., John J., Shearer M., Kerr I.M., Stark G.R.;
RT   "Use of a selectable marker regulated by alpha interferon to obtain
RT   mutations in the signaling pathway.";
RL   Mol. Cell. Biol. 9:4605-4612(1989).
//